Clinical trial
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or…
NCT00398073 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00398073 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma |
| Official title | Injection of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Mouse gp100 DNA: A Pilot Study to Compare Intramuscular Jet Injection With Particle Mediated Delivery |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Biological, Device, Other |
| Interventions | mouse gp100 plasmid DNA vaccine, The Dermal PowderMed® devices, intramuscularly (IM injection) |
| Enrollment | 35 |
| Start date | Oct 1, 2006 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Nov 10, 2006 |
| Last update posted | Mar 16, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: